VANGUARD® PLUS 5
Injectable
Description 



VANGUARD® PLUS 5 contains attenuated strains of canine distemper (CD) virus, canine adenovirus-2 (CAV-2), canine parvovirus (CPV), and canine parainfluenza (CPI) virus propagated on an established canine cell line.


The freeze-dried components are rehydrated with a sterile diluent. 


The PLUS in VANGUARD PLUS vaccines refers to the high-titer, low-passage canine parvovirus (CPV) component, which provides added immunogenicity that can override appreciable levels of maternal CPV antibodies in puppies 6 weeks of age or older. 


All VANGUARD PLUS vaccines contain an attenuated strain of canine adenovirus-2 (CAV-2), which protects against CAV-2 respiratory disease and against infectious canine hepatitis (ICH) caused by the closely related canine adenovirus-1 (CAV-1). The CAV-2 component provides this dual protection without causing postvaccination side effects (uveitis and corneal opacity) sometimes associated with conventional CAV-1 vaccines. 
Approved Uses 

VANGUARD PLUS 5 is approved for: 
Vaccination of healthy dogs as an aid in preventing disease caused by CD, ICH caused by CAV-1, CAV-2 respiratory disease, CPV enteritis, and respiratory disease caused by CPI virus. 


Vaccination of healthy dogs 6 weeks of age or older. 
Key Features 


The CAV-2 component in VANGUARD PLUS vaccines cross-immunizes against CAV-1 to protect dogs against ICH without producing postvaccination side effects, including uveitis and corneal opacity, sometimes attributed to CAV-1 vaccines.